Global Benidipine Market Size To Worth USD 2.41 Billion By 2033 | CAGR of 5.43%
Category: HealthcareGlobal Benidipine Market Size To Worth USD 2.41 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Benidipine Market Size is Expected to Grow from USD 1.42 Billion in 2023 to USD 2.41 Billion By 2033, at a CAGR of 5.43% during the Forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 240 pages with 120 Market data tables and figures & charts from the report on the "Global Benidipine Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Capsules, Tablets, and Others), By Indications (Angina Pectoris, Hypertension, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/benidipine-market
The benidipine market is a pharmaceutical industry that develops, produces, and commercializes calcium channel blockers for hypertension and ischemic heart diseases like angina pectoris. Benidipine regulates blood pressure by relaxing blood vessels and reducing pressure, allowing the heart to pump more blood, normalizing blood pressure in high-pressure patients. The marketed products include Bendicop-4, BENIDIN, and Benitowa-Trio. The rising prevalence of hypertension, affecting 1.3 billion people globally, leads to increased demand for benidipine medications. Government initiatives, such as the India Hypertension Control Initiative (IHCI) and the "25 by 25" goal to reduce premature mortality due to non-communicable diseases (NCDs) by 25% by 2025, drive market growth. Angina, a common symptom of ischemic heart disease, is a significant global health concern, doubling the risk of major cardiovascular events and causing 4.1 million deaths annually in Europe. The increasing prevalence of angina pectoris among populations accelerates the demand for calcium channel blockers, resulting in market expansion. However, adverse effects with the repeated use of benidipine may restrict the growth of the market.
The tablets segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the dosage form, the global benidipine market is categorized as capsules, tablets, and others. Among these, the tablets segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is ascribed to its ease of administration, patient compliance, enhanced stability, enhanced physiological activity, precise dosing, efficacy, novel drug delivery systems, and rapid action onset.
The hypertension segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the indications, the global benidipine market is categorized as angina pectoris, hypertension, and others. Among these, the hypertension segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is driven by hypertension prevalence, geriatric population, sedentary lifestyles, obesity, and increased use of benidipine for hypertension management due to its effectiveness.
The hospital pharmacies segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global benidipine market is categorized as angina pectoris, hypertension, and others. Among these, the hospital pharmacies segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is attributed to the availability of a wide range of benidipine medications, enhanced medication adherence, counseling and dispensing facilities, and personalized medications.
Asia Pacific is expected to hold the greatest share of the global benidipine market over the forecast period.
Get more details on this report -
Asia Pacific is expected to hold the greatest share of the global benidipine market over the forecast period. High rates of hypertension and cardiovascular diseases, a significant patient population in countries like China and India, and rising healthcare expenditures are driving market expansion. Government efforts to improve healthcare infrastructure and promote antihypertensive drug use are driving growth. Advances in drug delivery methods and the growing elderly population in the Asia Pacific are increasing the need for effective treatments.
North America is predicted to grow at the fastest CAGR throughout the estimated period. The growth of the hypertension market is driven by high prevalence, increasing awareness, well-established healthcare systems, demand for innovative treatments, key pharmaceutical companies, ongoing research, and the growing elderly population in North America, who are more prone to cardiovascular conditions, particularly hypertension and angina pectoris.
Major key players in the global benidipine market are Lupin Limited, Mylan N.V., Torrent Pharmaceuticals Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Johnson and Johnson, AbbVie Inc., Bayer AG, Kyowa Kirin Co., Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In January 2025, SSY Group Limited, a pharmaceutical company, received approval from the National Medical Products Administration of China for its Benidipine Hydrochloride, a treatment for primary hypertension and angina pectoris, to be marketed as a bulk drug. This move could enhance the company's product offerings and potentially strengthen its position in the market, benefiting shareholders and investors.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global benidipine market based on the below-mentioned segments:
Global Benidipine Market, By Dosage Form
- Capsules
- Tablets
- Others
Global Benidipine Market, By Indications
- Angina Pectoris
- Hypertension
- Others
Global Benidipine Market, By Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Others
Global Benidipine Market, By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?